Investing.com -- Teva Pharma Industries Ltd ADRs (NYSE:TEVA) declined over 3% in premarket trading Monday after the company announced it will discontinue its Phase 2 TOPAS-MSA study of emrusolmin (TEV-'286) following an interim futility analysis.
The decision came after an independent data monitoring committee recommended halting the trial based on a prespecified interim analysis. The analysis met the predefined futility criterion, indicating a low probability of the study meeting its primary efficacy endpoint if continued. No safety concerns were identified in the interim analysis.
The TOPAS-MSA study was evaluating emrusolmin in adults with multiple system atrophy (MSA), a rare neurodegenerative disorder. The randomized, double-blind, placebo-controlled Phase 2 study was designed to enroll approximately 350 participants to receive emrusolmin 300 mg or placebo for approximately 48 weeks.
Emrusolmin is being developed in partnership with MODAG GmbH. The drug received Orphan Drug designation from the U.S. Food and Drug Administration for MSA in 2022 and Fast Track designation in September 2025.
Teva said the decision concerns TOPAS-MSA specifically and does not represent a final decision on the broader emrusolmin program. The company plans to conduct a comprehensive analysis of the TOPAS-MSA data and available data from the open-label extension study of emrusolmin in MSA.
"While we are disappointed by the outcome of this interim analysis for the Phase 2 study, we remain deeply committed to learning everything we can from these data," said Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer at Teva.
MSA affects about 40,000 people in the U.S., EU, and Japan, with about 6,000 new cases diagnosed annually.
Original Article
Teva shares slide after drug trial discontinuation
uniQure stock jumps as FDA accepts Huntington's therapy filing
Buy These AI Infrastructure Stocks Amid Midterm Election Risks, Bernstein Says
